利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.058 秒)

    1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
    7.
    发明申请
    1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE 审中-公开

    公开(公告)号：US20100081825A1

    公开(公告)日：2010-04-01

    申请号：US12444275

    申请日：2007-10-05

    申请人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Kazunari Sakagami ,  Masato Hayashi ,  Shuhei Kashiwa ,  Katsunori Omodera

    发明人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Kazunari Sakagami ,  Masato Hayashi ,  Shuhei Kashiwa ,  Katsunori Omodera

    IPC分类号： C07D211/58 ,  C07D401/10

    CPC分类号： C07D405/12 ,  C07D211/58 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D409/12

    摘要： Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

    摘要翻译： 公开了一种药物组合物，其包含式（I）表示的化合物或其药学上可接受的盐作为活性成分，其对黑色素浓缩激素受体具有拮抗作用。 由于其对MCH受体的拮抗活性，药物组合物可用于预防或治疗诸如抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症， 社会焦虑障碍），注意力缺陷障碍，躁狂症，躁狂抑郁障碍，精神分裂症，情绪障碍，压力，睡眠障碍，发作，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍， 糖尿病，心血管疾病，高血压，血脂异常，心肌梗死，运动障碍（如帕金森病，癫痫，惊厥，震颤），药物滥用和药物成瘾。

    Dicarboxylic acid derivatives
    8.
    发明授权
    Dicarboxylic acid derivatives 失效
    二羧酸衍生物

    公开(公告)号：US06770676B2

    公开(公告)日：2004-08-03

    申请号：US10297479

    申请日：2002-12-06

    申请人： Atsuro Nakazato ,  Toshihito Kumagai ,  Kosuke Kanuma ,  Kazunari Sakagami

    发明人： Atsuro Nakazato ,  Toshihito Kumagai ,  Kosuke Kanuma ,  Kazunari Sakagami

    IPC分类号： C07C6113

    CPC分类号： C07C229/50 ,  C07C2602/18

    摘要： The present invention relates to 2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives represented by the formula: the pharmaceutically acceptable salts thereof, or the hydrates thereof. The compounds of the present invention are useful as a medicament, and in particular, are useful as modulators acting on group 2 metabotropic glutamate receptors, having effects for treating and/or preventing psychiatric disorders such as schizophrenia, anxiety and its associated diseases, depression, bipolar disorder, and epilepsy; and/or neurological diseases such as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, dyskinesia associated with muscular stiffness, cerebral ischemia, cerebral failure, myelopathy, and head trauma.

    摘要翻译： 本发明涉及由下式表示的2-氨基-6-氟双环[3.1.0]己烷-2,6-二羧酸衍生物或其药学上可接受的盐或其水合物。 本发明的化合物可用作药物，特别是可用作作用于组2代谢型谷氨酸受体的调节剂，具有治疗和/或预防精神病学障碍如精神分裂症，焦虑及其相关疾病，抑郁症， 双相障碍和癫痫; 和/或神经系统疾病如药物依赖性，认知障碍，阿尔茨海默病，亨廷顿氏舞蹈病，帕金森病，与肌肉僵硬相关的运动障碍，脑缺血，脑衰竭，脊髓病和头部创伤。

    7-piperidinoalkyl-3, 4-Dihydroquinolone derivative
    9.
    发明授权
    7-piperidinoalkyl-3, 4-Dihydroquinolone derivative 失效
    7-哌啶子基烷基-3,4-二氢喹诺酮衍生物

    公开(公告)号：US08461182B2

    公开(公告)日：2013-06-11

    申请号：US13122281

    申请日：2009-09-30

    申请人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    发明人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    IPC分类号： A61K31/04 ,  C07D215/38

    CPC分类号： C07D401/06 ,  C07D401/14

    摘要： PROBLEMTo provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action.SOLUTIONA compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

    摘要翻译： 提供用于预防或治疗抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症或社会焦虑症）的新型化合物，其药学上可接受的盐或水合物，注意力 缺陷障碍，躁狂症，躁狂抑郁症，精神分裂症，情绪障碍，压力，睡眠障碍，攻击，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍，食欲过盛，贪食症， 基于黑色素浓度激素受体（MCH受体）拮抗作用的心血管疾病，高血压，血脂异常，心肌梗塞，运动障碍（例如帕金森病，癫痫，惊厥或震颤），药物滥用，药物成瘾或性功能障碍。 解决方案由式（I）表示的化合物，其药学上可接受的盐或其水合物。

    7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE
    10.
    发明申请
    7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE 失效
    7-哌啶二醇-3,4-二氢喹啉酮衍生物

    公开(公告)号：US20110178304A1

    公开(公告)日：2011-07-21

    申请号：US13122281

    申请日：2009-09-30

    申请人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    发明人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    IPC分类号： C07D401/10

    CPC分类号： C07D401/06 ,  C07D401/14

    摘要： Problem To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action.Solution A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

    摘要翻译： 问题提供用于预防或治疗抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症或社会焦虑症）的新型化合物，其药学上可接受的盐或水合物，注意力 缺陷障碍，躁狂症，躁狂抑郁症，精神分裂症，情绪障碍，压力，睡眠障碍，攻击，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍，食欲过盛，贪食症， 基于黑色素浓度激素受体（MCH受体）拮抗作用的心血管疾病，高血压，血脂异常，心肌梗塞，运动障碍（例如帕金森病，癫痫，惊厥或震颤），药物滥用，药物成瘾或性功能障碍。 溶液由式（I）表示的化合物，其药学上可接受的盐或其水合物。